MX389296B - Metodo para tratar cancer urotelial del tracto inferior. - Google Patents

Metodo para tratar cancer urotelial del tracto inferior.

Info

Publication number
MX389296B
MX389296B MX2018013432A MX2018013432A MX389296B MX 389296 B MX389296 B MX 389296B MX 2018013432 A MX2018013432 A MX 2018013432A MX 2018013432 A MX2018013432 A MX 2018013432A MX 389296 B MX389296 B MX 389296B
Authority
MX
Mexico
Prior art keywords
lower tract
urothelial cancer
treating lower
tract urothelial
antimetabolite
Prior art date
Application number
MX2018013432A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013432A (es
Inventor
Cheryl Larrivee-Elkins
Christopher Cutie
Christopher Searcy
Dennis Giesing
Purnanand Sarma
Vikas Agarwal
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2018013432A publication Critical patent/MX2018013432A/es
Publication of MX389296B publication Critical patent/MX389296B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
MX2018013432A 2016-05-06 2017-05-05 Metodo para tratar cancer urotelial del tracto inferior. MX389296B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US201762443614P 2017-01-06 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Publications (2)

Publication Number Publication Date
MX2018013432A MX2018013432A (es) 2019-08-12
MX389296B true MX389296B (es) 2025-03-20

Family

ID=60203435

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013432A MX389296B (es) 2016-05-06 2017-05-05 Metodo para tratar cancer urotelial del tracto inferior.
MX2021013461A MX2021013461A (es) 2016-05-06 2018-11-01 Metodo para tratar cancer urotelial del tracto inferior.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013461A MX2021013461A (es) 2016-05-06 2018-11-01 Metodo para tratar cancer urotelial del tracto inferior.

Country Status (23)

Country Link
US (1) US20190388338A1 (cg-RX-API-DMAC7.html)
EP (2) EP3452053B1 (cg-RX-API-DMAC7.html)
JP (3) JP7712055B2 (cg-RX-API-DMAC7.html)
KR (2) KR102435709B1 (cg-RX-API-DMAC7.html)
CN (2) CN118453872A (cg-RX-API-DMAC7.html)
AU (1) AU2017261371B2 (cg-RX-API-DMAC7.html)
CA (1) CA3023274A1 (cg-RX-API-DMAC7.html)
ES (1) ES2940227T3 (cg-RX-API-DMAC7.html)
FI (1) FI3452053T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221544T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060965T2 (cg-RX-API-DMAC7.html)
IL (2) IL295592A (cg-RX-API-DMAC7.html)
LT (1) LT3452053T (cg-RX-API-DMAC7.html)
MX (2) MX389296B (cg-RX-API-DMAC7.html)
NZ (3) NZ787786A (cg-RX-API-DMAC7.html)
PL (1) PL3452053T3 (cg-RX-API-DMAC7.html)
PT (1) PT3452053T (cg-RX-API-DMAC7.html)
RS (1) RS64032B1 (cg-RX-API-DMAC7.html)
RU (2) RU2022100624A (cg-RX-API-DMAC7.html)
SG (2) SG10201913416PA (cg-RX-API-DMAC7.html)
SI (1) SI3452053T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300047T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017193098A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
CA3071014A1 (en) * 2017-07-25 2019-01-31 Taris Biomedical Llc Methods of treating tumor metastasis
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
WO2010151896A1 (en) 2009-06-26 2010-12-29 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
EP2512581B1 (en) 2009-12-17 2021-02-17 TARIS Biomedical LLC Implantable device with intravesical tolerability
KR20130109025A (ko) * 2010-06-02 2013-10-07 아브락시스 바이오사이언스, 엘엘씨 방광암의 치료 방법
LT2600800T (lt) 2010-08-05 2021-01-11 Taris Biomedical Llc Ureteralinio stento pavidalo vaisto vartojimo įtaisas ir rinkinys
US9107816B2 (en) 2011-02-04 2015-08-18 Taris Biomedical Llc Implantable device for controlled dissolution and diffusion of low solubility drug
JP6639228B2 (ja) * 2012-03-29 2020-02-05 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
LT2890384T (lt) * 2012-08-31 2022-01-10 Taris Biomedical Llc Vaistų pateikimo sistemos ir kraujo vėžio gydymo būdai, apimantys oksaliplatiną
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
WO2014138214A1 (en) 2013-03-05 2014-09-12 Taris Biomedical, Inc. Drug delivery devices and methods for controlled drug release through device orifice
CN105209012B (zh) 2013-03-15 2019-02-01 塔里斯生物医药公司 用于药物递送的药物递送装置和方法
BR112015022433B1 (pt) 2013-03-15 2022-06-21 Taris Biomedical Llc Dispositivo de liberação de droga intravesical
HRP20201421T1 (hr) 2013-08-19 2020-12-11 Taris Biomedical Llc Uređaji za davanje više jedinica lijeka
LT3113782T (lt) * 2014-03-06 2022-11-25 Taris Biomedical Llc Vaisto tiekimo sistemos ir būdai, skirti šlapimo pūslės vėžio gydymui gemcitabinu
AU2015279674B2 (en) 2014-06-26 2020-07-23 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법

Also Published As

Publication number Publication date
RU2018142908A (ru) 2020-06-08
KR20190005204A (ko) 2019-01-15
WO2017193098A1 (en) 2017-11-09
NZ787824A (en) 2025-10-31
BR112018072551A2 (pt) 2019-02-19
EP3452053B1 (en) 2022-12-14
RS64032B1 (sr) 2023-04-28
RU2022100624A (ru) 2022-02-09
US20190388338A1 (en) 2019-12-26
NZ748252A (en) 2025-10-31
SI3452053T1 (sl) 2023-03-31
EP3452053A1 (en) 2019-03-13
SG11201809838VA (en) 2018-12-28
EP4209221A1 (en) 2023-07-12
CN109475571A (zh) 2019-03-15
PT3452053T (pt) 2023-03-03
KR102435709B1 (ko) 2022-08-25
HUE060965T2 (hu) 2023-04-28
MX2018013432A (es) 2019-08-12
KR20220123317A (ko) 2022-09-06
PL3452053T3 (pl) 2023-05-08
NZ787786A (en) 2025-10-31
EP3452053A4 (en) 2019-12-25
CA3023274A1 (en) 2017-11-09
IL262746B (en) 2022-09-01
SMT202300047T1 (it) 2023-03-17
LT3452053T (lt) 2023-02-10
HRP20221544T1 (hr) 2023-02-17
IL262746A (en) 2018-12-31
MX2021013461A (es) 2021-12-10
JP7712055B2 (ja) 2025-07-23
SG10201913416PA (en) 2020-03-30
AU2017261371A1 (en) 2018-12-13
RU2764747C2 (ru) 2022-01-20
AU2017261371B2 (en) 2023-07-06
RU2018142908A3 (cg-RX-API-DMAC7.html) 2020-08-31
IL295592A (en) 2022-10-01
CN118453872A (zh) 2024-08-09
ES2940227T3 (es) 2023-05-04
JP2019514970A (ja) 2019-06-06
JP2022009327A (ja) 2022-01-14
FI3452053T3 (fi) 2023-04-12
JP2024028881A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2023006304A (es) Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
JOP20190285A1 (ar) استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد
MX2021013461A (es) Metodo para tratar cancer urotelial del tracto inferior.
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
MX2017012824A (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
EA201991818A1 (ru) Лечение рака
PH12017501879A1 (en) Methods for treating cancer
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2018014938A (es) Combinaciones farmaceuticas para el tratamiento del cancer.
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА